The Interleukin-10 Promoter Polymorphism rs1800872 (-592C>A), Contributes to Cancer Susceptibility: Meta-Analysis of 16 785 Cases and 19 713 Controls

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ding, Qi ^a   Shi, Ying ^a   Fan, Bo ^a   Fan, Zhijiang ^a   Ding, Li ^a   Li, Feng ^a   Tu, Wenjian ^a   Jin, Xiaohua ^a   Wang, Jing ^a  

^a the First Affiliated Hospital of Soochow University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IL10 GENE; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; PROMOTER REGION; PROSTATE CANCER; PUBLISHING; RISK REDUCTION; SENSITIVITY ANALYSIS; SMOKING; STOMACH CANCER; UTERINE CERVIX CANCER;

CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; RISK FACTORS;

EID: 84874550770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057246     Document Type: Article

References (94)

1. Risch N, Merikangas K, (1996) The future of genetic studies of complex human diseases. Science 273: 1516-1517.
2. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M, (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15: 61-76.
3. Huang S, Ullrich SE, Bar-Eli M, (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19: 697-703.
4. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, et al. (1996) Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 104: 1-5.
5. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM, (2003) The dual role of IL-10. Trends Immunol 24: 36-43.
6. Sharma N, Luo J, Kirschmann DA, O'Malley Y, Robbins ME, et al. (1999) A novel immunological model for the study of prostate cancer. Cancer Res 59: 2271-2276.
7. Stearns ME, Wang M, Hu Y, Garcia FU, Rhim J, (2003) Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. Clin Cancer Res 9: 1191-1199.
8. Asadullah K, Sterry W, Volk HD, (2003) Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55: 241-269.
9. Spits H, de Waal Malefyt R, (1992) Functional characterization of human IL-10. Int Arch Allergy Immunol 99: 8-15.
10. Kingo K, Ratsep R, Koks S, Karelson M, Silm H, et al. (2005) Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 37: 111-113.
11. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, et al. (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24: 1-8.
12. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, et al. (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95: 9465-9470.
13. Purdue MP, Sakoda LC, Graubard BI, Welch R, Chanock SJ, et al. (2007) A case-control investigation of immune function gene polymorphisms and risk of testicular germ cell tumors. Cancer Epidemiol Biomarkers Prev 16: 77-83.
14. Hart K, Landvik NE, Lind H, Skaug V, Haugen A, et al. (2011) A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer 71: 123-129.
15. Guzowski D, Chandrasekaran A, Gawel C, Palma J, Koenig J, et al. (2005) Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 16: 154-166.
16. Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, et al. (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28: 1728-1733.
17. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, et al. (2009) Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20: 1739-1751.
18. Liu J, Song B, Bai X, Liu W, Li Z, et al. (2010) Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 10: 456.
19. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, et al. (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19: 119-124.
20. Alpizar-Alpizar W, Perez-Perez GI, Une C, Cuenca P, Sierra R, (2005) Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. Clin Exp Med 5: 169-176.
21. Kong F, Liu J, Liu Y, Song B, Wang H, et al. (2010) Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 29: 72.
22. Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, et al. (2005) Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225: 207-214.
23. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, et al. (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69: 874-885.
24. Tseng LH, Lin MT, Shau WY, Lin WC, Chang FY, et al. (2006) Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 67: 127-133.
25. Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, et al. (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089: 104-109.
26. Crusius JB, Canzian F, Capella G, Pena AS, Pera G, et al. (2008) Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol 19: 1894-1902.
27. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, et al. (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107: 4101-4108.
28. Schoof N, von Bonin F, Konig IR, Mossner R, Kruger U, et al. (2009) Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case-control study. Genes Immun 10: 586-590.
29. Zeng X, Li Y, Liu T, Zhang J (2011) Diverse H. pylori strains, IL-10 promoter polymorphisms with high morbidity of gastric cancer in Hexi area of Gansu Province, China. Mol Cell Biochem.
30. Shekari M, Kordi-Tamandani DM, Malekzadeh K, Sobti RC, Karimi S, et al. (2011) Effect of Anti-inflammatory (IL-4, IL-10) Cytokine Genes in Relation to Risk of Cervical Carcinoma. Am J Clin Oncol.
31. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, et al. (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 14: 3777-3784.
32. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, et al. (2007) Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol 22: 1443-1449.
33. Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, et al. (2006) Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and-10 genes. Int J Cancer 118: 649-657.
34. Garcia-Gonzalez MA, Lanas A, Quintero E, Nicolas D, Parra-Blanco A, et al. (2007) Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol 102: 1878-1892.
35. Yao JG, Gao LB, Liu YG, Li J, Pang GF, (2008) Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 388: 84-88.
36. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, et al. (2007) High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 68: 698-704.
37. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, et al. (2005) IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96: 241-246.
38. Howell WM, Turner SJ, Bateman AC, Theaker JM, (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2: 25-31.
39. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, et al. (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124: 1193-1201.
40. Cacev T, Radosevic S, Krizanac S, Kapitanovic S, (2008) Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29: 1572-1580.
41. Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C, (2005) Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15: 53-60.
42. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, et al. (2010) Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 70: 341-352.
43. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, et al. (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 29: 573-578.
44. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, et al. (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43: 472-475.
45. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, et al. (2005) Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer 15Suppl 3: 282-290.
46. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, et al. (2006) Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30.
47. Erdogan M, Karadeniz M, Ozbek M, Ozgen AG, Berdeli A, (2008) Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population. J Endocrinol Invest 31: 750-754.
48. Wei YS, Kuang XH, Zhu YH, Liang WB, Yang ZH, et al. (2007) Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens 70: 12-17.
49. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, et al. (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103: 3529-3534.
50. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, et al. (2003) Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 104: 617-623.
51. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, et al. (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90: 113-115.
52. Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, et al. (2002) Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 184: 57-63.
53. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, et al. (2002) Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12: 465-469.
54. Munro LR, Johnston PW, Marshall NA, Canning SJ, Hewitt SG, et al. (2003) Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma 44: 2083-2088.
55. Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Konsgen D, et al. (2007) Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol 104: 680-685.
56. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, et al. (2008) Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639: 89-100.
57. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, et al. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28: 704-712.
58. Kamangar F, Abnet CC, Hutchinson AA, Newschaffer CJ, Helzlsouer K, et al. (2006) Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 17: 117-125.
59. Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, et al. (2004) Polymorphisms in interleukin-2,-6, and-10 are not associated with gastric cardia or esophageal cancer in a high-risk chinese population. Cancer Epidemiol Biomarkers Prev 13: 1547-1549.
60. Liu J, Song B, Wang JL, Li ZJ, Li WH, et al. (2011) Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol 17: 1362-1367.
61. Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, et al. (2005) Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 29: 141-152.
62. Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, et al. (2006) Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci 1089: 98-103.
63. He B, Pan Y, Xu Y, Nie Z, Chen L, et al. (2012) Increased risk for gastric cancer in carriers of the lymphotoxin-alpha+252G variant infected by Helicobacter pylori. Genet Test Mol Biomarkers 16: 9-14.
64. Ando T, Ishikawa T, Kato H, Yoshida N, Naito Y, et al. (2009) Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter pylori infection. Int J Cancer 125: 2595-2602.
65. Kang JM, Kim N, Lee DH, Park JH, Lee MK, et al. (2009) The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. J Clin Gastroenterol 43: 420-428.
66. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, et al. (2005) The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50: 291-297.
67. Colakogullari M, Ulukaya E, Yilmaztepe Oral A, Aymak F, Basturk B, et al. (2008) The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 26: 283-290.
68. Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM, (2005) The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14: 1613-1618.
69. Zhang Z, Liu W, Jia X, Gao Y, Hemminki K, et al. (2004) Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta 342: 137-143.
70. Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, et al. (2007) Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 121: 2451-2457.
71. Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, et al. (2005) Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30: 41-45.
72. Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, et al. (2003) Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer 34: 19-26.
73. Li Y, Chang SC, Goldstein BY, Scheider WL, Cai L, et al. (2011) Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol 35: 362-368.
74. Andersen V, Egeberg R, Tjonneland A, Vogel U, (2012) Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study. BMC Cancer 12: 183.
75. Pooja S, Chaudhary P, Nayak LV, Rajender S, Saini KS, et al. (2012) Polymorphic variations in IL-1beta, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine 60: 122-128.
76. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, et al. (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617: 138-146.
77. Zhang Y, Wang MY, He J, Wang JC, Yang YJ, et al. (2012) Tumor necrosis factor-alpha induced protein 8 polymorphism and risk of non-Hodgkin's lymphoma in a Chinese population: a case-control study. PLoS One 7: e37846.
78. Lech-Maranda E, Baseggio L, Charlot C, Rigal D, Berger F, et al. (2007) Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 48: 2235-2238.
79. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ: 1-406.
80. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. Bmj 327: 557-560.
81. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, et al. (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14: 108-117.
82. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J, (2005) A method for meta-analysis of molecular association studies. Stat Med 24: 1291-1306.
83. Lim S, Crawley E, Woo P, Barnes PJ, (1998) Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 352: 113.
84. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, et al. (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30: 526-530.
85. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR, (2003) Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 31: 34-38.
86. Hutchinson IV, Pravica V, Hajeer A, Sinnott PJ, (1999) Identification of high and low responders to allografts. Rev Immunogenet 1: 323-333.
87. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, et al. (1994) Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371-2376.
88. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, et al. (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373.
89. Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030-1036.
90. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, et al. (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92: 1764-1772.
91. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, et al. (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48: 3282-3287.
92. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE, (2007) Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 166: 932-940.
93. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L, (2005) Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 175: 2684-2691.
94. Salazar-Onfray F, Petersson M, Franksson L, Matsuda M, Blankenstein T, et al. (1995) IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 154: 6291-6298.